Publication date context: 2026-02-20T14:35:48.000Z. As of that date ClinicalTrials.gov lists a study evaluating the performance of AI software paired with chest X rays to screen for osteoporosis and osteopenia in adults 50 years and older. The sponsor is Promedius Inc and the device under study is Osteo Signal. The trial is recruiting, and the record emphasizes a performance based comparison with conventional DXA.
What is the study design and scope?
The study evaluates performance of an AI assisted chest X ray screening approach for osteoporosis and osteopenia in adults aged 50 years and older. The AI software is applied to chest imaging and is compared to standard DXA scans to establish a baseline for screening performance. The Osteo Signal device is the instrument under evaluation. Promedius Inc sponsors the study and the record notes that recruitment is ongoing.
What outcomes are considered in this assessment?
Public sources indicate the focus on performance against the reference DXA method. The description does not specify numerical metrics in the record but implies a screening oriented objective rather than a diagnostic claim.
Who should care and what regulatory considerations apply?
Regulatory and quality teams in medical device programs should monitor this study as it may inform future submissions for AI aided imaging tools. Clinicians and radiology departments may see a shift in screening workflows, subject to regulatory clearance and evidence of safety and effectiveness.
What is the Osteo Signal device and what regulatory considerations apply?
Osteo Signal is the device under investigation in this study. The description in the trial record frames the device as an aid in screening for osteoporosis and osteopenia when used with chest X rays. As the study is evaluating performance and safety aspects, sponsors and investigators will align with MDR expectations for intended use, performance, and safety claims. Manufacturer statements would be identified as such and the data would be used to support regulatory assessment.
What is the timeline and what happens next?
The recruitment status is listed as ongoing. No dates are provided in the source text. Observers should await trial results and any regulatory submissions that may follow if performance meets predefined criteria.
FAQ
- 1. What is the Osteo Signal device used for in this study?
The device is used to support AI assisted chest X ray screening for osteoporosis and osteopenia.
- 2. Who is sponsoring the study?
Promedius Inc is listed as the sponsor.
- 3. What population is included?
Participants are adults aged 50 years and older who have osteoporosis or osteopenia as indicated by the study scope.
- 4. What is being compared in this study?
The study compares AI assisted chest X ray screening with AI software to standard DXA scanning for osteoporosis.
Conclusion
Current information describes a study that assesses a screening tool based on AI assisted imaging and chest X rays for osteoporosis. The trial compares this approach with DXA, and results could inform regulatory discussions and future submissions. Stakeholders should monitor the recruitment status and await results before drawing regulatory conclusions.
Disclaimer: This material is for professionals and is not legal advice. It reflects information from the source text and is not a substitute for regulatory guidance.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07421713?term=medical+device